CH676467A5 - - Google Patents
Download PDFInfo
- Publication number
- CH676467A5 CH676467A5 CH1336/87A CH133687A CH676467A5 CH 676467 A5 CH676467 A5 CH 676467A5 CH 1336/87 A CH1336/87 A CH 1336/87A CH 133687 A CH133687 A CH 133687A CH 676467 A5 CH676467 A5 CH 676467A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cells
- tripeptide
- els2
- arg
- pha
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229940124280 l-arginine Drugs 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 2
- 108010031650 Thy-1 Antigens Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002861 immature t-cell Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- -1 Boc group Chemical group 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102400000159 Thymopoietin Human genes 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT20027/86A IT1188646B (it) | 1986-04-09 | 1986-04-09 | Tripeptide ad attivita' immunostimolante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH676467A5 true CH676467A5 (enrdf_load_stackoverflow) | 1991-01-31 |
Family
ID=11163225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1336/87A CH676467A5 (enrdf_load_stackoverflow) | 1986-04-09 | 1987-04-07 |
Country Status (17)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995025531A1 (en) * | 1994-03-18 | 1995-09-28 | Ivan Nikolaevich Golovistikov | Means for treating auto-immune diseases and method of treatment |
| US6040187A (en) * | 1994-03-18 | 2000-03-21 | Ivan Nikolaevich Golovistikov | Method of determining the suppressor cell component of human immune status and a means for the realization thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130285D0 (en) * | 2001-12-19 | 2002-02-06 | Astrazeneca Ab | Chemical process |
| GB0130286D0 (en) * | 2001-12-19 | 2002-02-06 | Astrazeneca Ab | Chemical process |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778426A (en) * | 1970-12-16 | 1973-12-11 | Research Corp | Therapeutically useful polypeptides |
| US4215112A (en) * | 1979-03-14 | 1980-07-29 | Ortho Pharmaceutical Corporation | Tripeptides and methods |
-
1986
- 1986-04-09 IT IT20027/86A patent/IT1188646B/it active
-
1987
- 1987-04-06 IE IE88187A patent/IE59806B1/en not_active IP Right Cessation
- 1987-04-07 CH CH1336/87A patent/CH676467A5/it not_active IP Right Cessation
- 1987-04-07 SE SE8701457A patent/SE8701457L/ not_active Application Discontinuation
- 1987-04-08 CA CA000534201A patent/CA1322715C/en not_active Expired - Fee Related
- 1987-04-08 NL NL8700827A patent/NL8700827A/nl not_active Application Discontinuation
- 1987-04-08 AU AU71182/87A patent/AU597048B2/en not_active Ceased
- 1987-04-09 GR GR870568A patent/GR870568B/el unknown
- 1987-04-09 FR FR878705021A patent/FR2597107B1/fr not_active Expired - Fee Related
- 1987-04-09 JP JP62087896A patent/JPH0645637B2/ja not_active Expired - Lifetime
- 1987-04-09 AR AR87307260A patent/AR242799A1/es active
- 1987-04-09 GB GB8708492A patent/GB2189491B/en not_active Expired - Fee Related
- 1987-04-09 AT AT0088387A patent/ATA88387A/de not_active Application Discontinuation
- 1987-04-09 ES ES8701042A patent/ES2003043A6/es not_active Expired
- 1987-04-09 KR KR870003455A patent/KR870010080A/ko not_active Ceased
- 1987-04-09 BE BE8700377A patent/BE1000263A4/fr not_active IP Right Cessation
- 1987-04-09 DE DE19873712050 patent/DE3712050A1/de active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995025531A1 (en) * | 1994-03-18 | 1995-09-28 | Ivan Nikolaevich Golovistikov | Means for treating auto-immune diseases and method of treatment |
| US6040187A (en) * | 1994-03-18 | 2000-03-21 | Ivan Nikolaevich Golovistikov | Method of determining the suppressor cell component of human immune status and a means for the realization thereof |
| US6150326A (en) * | 1994-03-18 | 2000-11-21 | Leonid Yazonovich Kacharava | Means for treating autoimmune diseases and method for the treatment thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0645637B2 (ja) | 1994-06-15 |
| FR2597107A1 (fr) | 1987-10-16 |
| GB2189491B (en) | 1990-02-21 |
| IE870881L (en) | 1987-10-09 |
| GB2189491A (en) | 1987-10-28 |
| FR2597107B1 (fr) | 1991-02-22 |
| IT8620027A1 (it) | 1987-10-09 |
| AR242799A1 (es) | 1993-05-31 |
| IT8620027A0 (it) | 1986-04-09 |
| DE3712050C2 (enrdf_load_stackoverflow) | 1992-02-13 |
| DE3712050A1 (de) | 1987-10-15 |
| NL8700827A (nl) | 1987-11-02 |
| JPS62267296A (ja) | 1987-11-19 |
| CA1322715C (en) | 1993-10-05 |
| IT1188646B (it) | 1988-01-20 |
| ATA88387A (de) | 1996-05-15 |
| ES2003043A6 (es) | 1988-10-01 |
| AU597048B2 (en) | 1990-05-24 |
| SE8701457D0 (sv) | 1987-04-07 |
| GB8708492D0 (en) | 1987-05-13 |
| GR870568B (en) | 1987-08-12 |
| IE59806B1 (en) | 1994-04-06 |
| KR870010080A (ko) | 1987-11-30 |
| BE1000263A4 (fr) | 1988-09-27 |
| AU7118287A (en) | 1987-10-15 |
| SE8701457L (sv) | 1987-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4428938A (en) | Peptides affecting the immune regulation and a process for their preparation | |
| Courtenay et al. | Immunisation against heterologous type II collagen induces arthritis in mice | |
| Sachs | Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia | |
| US4395404A (en) | Synthetic thymosin β3 and β4 analogues | |
| CH678059A5 (enrdf_load_stackoverflow) | ||
| US4002740A (en) | Tridecapeptide compositions and methods | |
| Lee et al. | Murine B cell hybridomas bearing ligand-inducible Fc receptors for IgE. | |
| JPS61218598A (ja) | バ−ソポイエチン | |
| AU694602B2 (en) | Novel peptide | |
| CH676467A5 (enrdf_load_stackoverflow) | ||
| CH678328A5 (enrdf_load_stackoverflow) | ||
| JPS6118560B2 (enrdf_load_stackoverflow) | ||
| Dy et al. | Histamine-producing cell stimulating factor (HCSF) and interleukin 3 (IL 3): evidence for two distinct molecular entities. | |
| JPS6327360B2 (enrdf_load_stackoverflow) | ||
| IT9048102A1 (it) | Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono | |
| GB2185486A (en) | Conjugate of alpha-melanotropin with p-L-sarcolysine (melphalan) | |
| IT9019630A1 (it) | Peptidi sdk, un procedimento per la loro preparazione e composizioni terapeutiche che li contengono | |
| CN110577580B (zh) | 一种多发性骨髓瘤治疗疫苗 | |
| JPH0672152B2 (ja) | チモシンα１―フラグメント及び該化合物を含有する免疫調節剤 | |
| Firer et al. | Induction of Fc epsilon receptors on normal murine T cells and IgE binding factor (s) by cross-linked IgE or IgE-pulsed adherent cells | |
| GB1585736A (en) | Polypeptides and methods for their production | |
| IT9020818A1 (it) | Polipeptide contenente zuccheri ad attivita' immunomodulante ed antitumorale procedimento per il suo isolamento e composizioni farmaceutiche che lo contengono |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |